KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Long-Term Investments (2016 - 2020)

Inovio Pharmaceuticals' Long-Term Investments history spans 11 years, with the latest figure at $434387.0 for Q4 2020.

  • For Q4 2020, Long-Term Investments changed N/A year-over-year to $434387.0; the TTM value through Dec 2020 reached $434387.0, changed N/A, while the annual FY2020 figure was $434387.0, N/A changed from the prior year.
  • Long-Term Investments for Q4 2020 was $434387.0 at Inovio Pharmaceuticals, down from $957567.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $22.4 million in Q1 2016 and bottomed at $434387.0 in Q4 2020.
  • The 5-year median for Long-Term Investments is $9.1 million (2017), against an average of $10.6 million.
  • The largest annual shift saw Long-Term Investments soared 8557.24% in 2016 before it plummeted 57.72% in 2017.
  • A 5-year view of Long-Term Investments shows it stood at $16.1 million in 2016, then plummeted by 43.5% to $9.1 million in 2017, then dropped by 29.63% to $6.4 million in 2018, then decreased by 0.9% to $6.3 million in 2019, then crashed by 93.13% to $434387.0 in 2020.
  • Per Business Quant, the three most recent readings for INO's Long-Term Investments are $434387.0 (Q4 2020), $957567.0 (Q3 2020), and $2.7 million (Q2 2020).